B7-H3 expression in colorectal cancer: Nuclear localization strongly predicts poor outcome in colon cancer

International Journal of Cancer

Volumn 131, Issue 11, 2012, Pages 2528-2536

  Ingebrigtsen, Vibeke Anett ^a,b   Boye, Kjetil ^a   Tekle, Christina ^a   Nesland, Jahn Martin ^a,b   Flatmark, Kjersti ^a   Fodstad, Oystein ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

colorectal cancer; nuclear B7 H3; prognostic marker

Indexed keywords

B7 H3 ANTIBODY; PROTEIN ANTIBODY; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CARCINOGENESIS; CELL FRACTIONATION; CELL MEMBRANE; CELL NUCLEUS; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; NUCLEAR LOCALIZATION SIGNAL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK REDUCTION; TUMOR CELL; TUMOR VASCULARIZATION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; B7 ANTIGENS; CARCINOMA; CELL MEMBRANE; CELL NUCLEUS; COLORECTAL NEOPLASMS; CYTOPLASM; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FIBROBLASTS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84867041172     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27566     Document Type: Article

References (50)

1. Ferlay J, Shin HR, Bray F, et al., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Edge DB, Compton CC, Fritz AG, et al., AJCC cancer staging manual. Seventh New York: Springerlink, 2010; 130.
3. Greene FL,. Staging of colon and rectal cancer: from endoscopy to molecular markers. Surg Endosc 2006; 20 (Suppl 2): S475-8.
4. O'Connell JB, Maggard MA, Ko CY, et al., Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96: 1420-5.
5. Gunderson LL, Jessup JM, Sargent DJ, et al., Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol 2010; 28: 264-71.
6. Pfister DG, Benson AB, III, Somerfield MR, et al., Clinical practice. Surveillance strategies after curative treatment of colorectal cancer. N Engl J Med 2004; 350: 2375-82.
7. Gray R, Barnwell J, McConkey C, et al., Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomized study. Lancet 2007; 370: 2020-9.
8. Andre T, Boni C, Navarro M, et al., Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-16.
9. Locker GY, Hamilton S, Harris J, et al., ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24: 5313-27.
10. Collins M, Ling V, Carreno BM, et al., The B7 family of immune-regulatory ligands. Genome Biol 2005; 6: 223.
11. Chapoval AI, Ni J, Lau JS, et al., B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunology 2001; 2: 269-74.
12. Suh WK, Gajewska BU, Okada H, et al., The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunology 2003; 4: 899-906.
13. Roth TJ, Sheinin Y, Lohse CM, et al., B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res 2007; 67: 7893-900.
14. Hashiguchi M, Kobori H, Ritprajak P, et al., Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses. Proc Natl Acad Sci USA 2008; 105: 10495-500.
15. Nagashima O, Harada N, Usui Y, et al., B7-H3 contributes to the development of pathogenic Th2 cells in a murine model of asthma. J Immunol 2008; 181: 4062-71.
16. Luo L, Chapoval AI, Flies DB, et al., B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells. J Immunol 2004; 173: 5445-50.
17. Ma L, Luo L, Qiao H, et al., Complete eradication of hepatocellular carcinomas by combined vasostatin gene therapy and B7H3-mediated immunotherapy. J Hepatol 2007; 46: 98-106.
18. Castriconi R, Dondero A, Augugliaro R, et al., Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci USA 2004; 101: 12640-5.
19. Leitner J, Klauser C, Pickl WF, et al., B7-H3 is a potent inhibitor of human T-cell activation: no evidence for B7-H3 and TREML2 interaction. Eur J Immunol 2009; 39: 1754-64.
20. Wu CP, Jiang JT, Tan M, et al., Relationship between co-stimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis. World J Gastroenterol 2006; 12: 457-9.
21. Zang X, Thompson RH, Al-Ahmadie HA, et al., B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci USA 2007; 104: 19458-63.
22. Boorjian SA, Sheinin Y, Crispen PL, et al., T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res 2008; 14: 4800-8.
23. Crispen PL, Sheinin Y, Roth TJ, et al., Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res 2008; 14: 5150-7.
24. Yamato I, Sho M, Nomi T, et al., Clinical importance of B7-H3 expression in human pancreatic cancer. Br J Cancer 2009; 101: 1709-16.
25. Loos M, Hedderich DM, Ottenhausen M, et al., Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer 2009; 9: 463.
26. Arigami T, Narita N, Mizuno R, et al., B7-h3 ligand expression by primary breast cancer and associated with regional nodal metastasis. Ann Surg 2010; 252: 1044-51.
27. Sun J, Chen LJ, Zhang GB, et al., Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma. Cancer Immunol Immunother 2010; 59: 1163-71.
28. Zang X, Sullivan PS, Soslow RA, et al., Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol 2010; 23: 1104-12.
29. Chen YW, Tekle C, Fodstad O, et al., The immunoregulatory protein human B7H3 is a tumor-associated antigen that regulates tumor cell migration and invasion. Curr Cancer Drug Targets 2008; 8: 404-13.
30. Liu H, Tekle C, Chen YW, et al., B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation. Mol Cancer Ther 2011.
31. Tekle C, Nygren MK, Chen YW, et al., B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes. Int J Cancer 2011.
32. Flatmark K, Bjornland K, Johannessen HO, et al., Immunomagnetic detection of micrometastatic cells in bone marrow of colorectal cancer patients. Clin Cancer Res 2002; 8: 444-9.
33. Boye K, Nesland JM, Sandstad B, et al., Nuclear S100A4 is a novel prognostic marker in colorectal cancer. Eur J Cancer 2010; 46: 2919-25.
34. Flatmark K, Pedersen KB, Nesland JM, et al., Nuclear localization of the metastasis-related protein S100A4 correlates with tumour stage in colorectal cancer. J Pathol 2003; 200: 589-95.
35. Schroder B, Wrocklage C, Pan C, et al., Integral and associated lysosomal membrane proteins. Traffic 2007; 8: 1676-86.
36. Goldman RD, Gruenbaum Y, Moir RD, et al., Nuclear lamins: building blocks of nuclear architecture. Genes Dev 2002; 16: 533-47.
37. Orend G, Hunter T, Ruoslahti E, et al., Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells. Oncogene 1998; 16: 2575-83.
38. Boorjian SA, Sheinin Y, Crispen PL, et al., T-cell co-regulatory molecule expression in renal angiomyolipoma and pulmonary lymphangioleiomyomatosis. Urology 2009; 74: 1359-64.
39. Kapiteijn E, Liefers GJ, Los LC, et al., Mechanisms of oncogenesis in colon versus rectal cancer. J Pathol 2001; 195: 171-8.
40. Frattini M, Balestra D, Suardi S, et al., Different genetic features associated with colon and rectal carcinogenesis. Clin Cancer Res 2004; 10: 4015-21.
41. Tweedle EM, Khattak I, Ang CW, et al., Low molecular weight heat shock protein HSP27 is a prognostic indicator in rectal cancer but not colon cancer. Gut 2010; 59: 1501-10.
42. Nielsen BS, Jorgensen S, Fog JU, et al., High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients. Clin Exp Metastasis 2011; 28: 27-38.
43. Wagstaff KM, Jans DA,. Importins and beyond: non-conventional nuclear transport mechanisms. Traffic 2009; 10: 1188-98.
44. Wang YN, Yamaguchi H, Hsu JM, et al., Nuclear trafficking of the epidermal growth factor receptor family membrane proteins. Oncogene 2010; 29: 3997-4006.
45. Ghebeh H, Lehe C, Barhoush E, et al., Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule. Breast Cancer Res 2010; 12: R48.
46. Kau TR, Way JC, Silver PA, et al., Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer 2004; 4: 106-17.
47. Carpenter G, Liao HJ,. Trafficking of receptor tyrosine kinases to the nucleus. Exp Cell Res 2009; 315: 1556-66.
48. Lo HW, Xia W, Wei Y, et al., Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res 2005; 65: 338-48.
49. Psyrri A, Yu Z, Weinberger PM, et al., Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 2005; 11: 5856-62.
50. Shaaban AM, Green AR, Karthik S, et al., Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res 2008; 14: 5228-35.